Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Childhood Cancer
93%
Pediatric Acute Myeloid Leukemia
67%
Acute Lymphoblastic Leukemia
58%
Pediatrics
58%
Chemotherapy
55%
Pontine Glioma
42%
Malignant Neoplasm
38%
Overall Survival
33%
Diseases
29%
Event Free Survival
27%
Adolescence
23%
Treatment Outcome
22%
Acute Myelogenous Leukemia
20%
Cancer Therapy
18%
Leukemia
18%
Pediatrics Patient
17%
Tumor
16%
Survival Rate
16%
Oncology
16%
Supportive Care
15%
Minimal Residual Disease
14%
Radiation Therapy
13%
Cytarabine
13%
High Risk Population
13%
Clinical Trial
13%
Vincristine
13%
Ganglioneuroblastoma
13%
Cancer
12%
Low and Middle Income Countries
12%
Ganglioglioma
12%
Retrospective Study
11%
Quality of Life
11%
Cohort Analysis
11%
Cancer-Related Fatigue
10%
Randomized Controlled Trial
9%
Doxorubicin
9%
Patient Referral
9%
Neoplasm
9%
Injection
9%
Health Care Personnel
9%
Cumulative Incidence
9%
Childhood Leukemia
9%
Wilms' Tumor
9%
Drug Resistance
8%
Prognostic Factor
8%
Infusion
8%
Reproductive Medicine
8%
Treatment Response
8%
Drug Megadose
8%
Keyphrases
Acute Myeloid Leukemia
95%
Pediatric Leukemia
74%
Childhood Acute Lymphoblastic Leukemia
61%
Diffuse Intrinsic Pontine Glioma
52%
Acute Lymphoblastic Leukemia
45%
Dutch
34%
Pediatric
33%
Children with Cancer
30%
Childhood Cancer
24%
Drug Resistance
23%
Overall Survival
23%
Cytarabine
20%
Pediatric Acute Lymphoblastic Leukemia
20%
Pediatric Patients
19%
Kenya
17%
Event-free Survival
17%
Leukemia Patients
16%
Quality of Life
16%
Leukemia
16%
Chemotherapy
16%
Pediatric Oncology
16%
Vincristine-induced Peripheral Neuropathy
16%
Methotrexate
16%
Health-related Quality of Life
16%
Randomized Controlled Trial
16%
Cellular Drugs
16%
L-asparaginase
15%
Newly Diagnosed
15%
Prednisolone
15%
Relapsed Acute Myeloid Leukemia
15%
Late Effects
14%
Childhood Cancer Patients
14%
Oncology
13%
Netherlands
13%
Radiotherapy
13%
Childhood Cancer Treatment
13%
Prognostic Significance
13%
Childhood Leukemia
12%
Supportive Care
12%
High Risk
12%
Tumor
12%
Deoxycytidine Kinase
12%
Treatment Outcome
11%
Survivors
11%
Ara-C
11%
Daunorubicin
11%
Pediatric Cancer Patients
11%
Acute Lymphoblastic Leukemia Cells
11%
Healthcare Providers
11%
Low-middle Income Countries
10%